Business Wire03.01.18
Cardiovascular Systems Inc. (CSI) has named Jeff Points as chief financial officer (CFO), effective immediately. As part of a planned succession, Points succeeds Larry Betterley as CFO and will report to Chairman, President and CEO Scott Ward.
“During his 10 years with CSI, Jeff has been a leader in our organization, most recently serving as vice president, corporate controller and treasurer,” stated Ward. “He will continue to be a key contributor as we build CSI for attractive growth and profitability.”
Points brings over 20 years of accounting and finance experience to the company. Prior to CSI, he served as assistant controller at Empi, a manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. Points also held various leadership positions at CliftonLarsonAllen, a national public accounting firm. He earned an MBA from the University of St. Thomas and a bachelor’s degree in business from Bethel University. Points is a licensed certified public accountant.
“The patient populations we serve are large and growing,” said Points. “I am honored to continue to pursue CSI’s Mission as we expand our ability to improve the outcomes of those suffering from critical limb ischemia and complex coronary lesions.”
After serving CSI for over a decade, Betterley plans to retire in August 2018. He will continue to serve CSI in a newly created role as vice president of administration and report to Ward. In this role, Betterley will serve as an executive leader within the company and will assist in the orderly transition of the CFO office.
“Larry has played an integral role in transforming CSI from an emerging medical device startup to an established and growing $200 million-plus atherectomy leader,” said Ward, “We deeply appreciate Larry’s leadership and extraordinary contributions to the company and sincerely thank him for his 10 years of service and commitment to our mission.”
Cardiovascular Systems Inc., based in St. Paul, Minn., develops and commercializes solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. Food and Drug Administration (FDA) granted the first 510(k) clearance for the use of the Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the Coronary Orbital Atherectomy System. To date, over 356,000 of CSI’s devices have been sold to U.S. institutions.
“During his 10 years with CSI, Jeff has been a leader in our organization, most recently serving as vice president, corporate controller and treasurer,” stated Ward. “He will continue to be a key contributor as we build CSI for attractive growth and profitability.”
Points brings over 20 years of accounting and finance experience to the company. Prior to CSI, he served as assistant controller at Empi, a manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. Points also held various leadership positions at CliftonLarsonAllen, a national public accounting firm. He earned an MBA from the University of St. Thomas and a bachelor’s degree in business from Bethel University. Points is a licensed certified public accountant.
“The patient populations we serve are large and growing,” said Points. “I am honored to continue to pursue CSI’s Mission as we expand our ability to improve the outcomes of those suffering from critical limb ischemia and complex coronary lesions.”
After serving CSI for over a decade, Betterley plans to retire in August 2018. He will continue to serve CSI in a newly created role as vice president of administration and report to Ward. In this role, Betterley will serve as an executive leader within the company and will assist in the orderly transition of the CFO office.
“Larry has played an integral role in transforming CSI from an emerging medical device startup to an established and growing $200 million-plus atherectomy leader,” said Ward, “We deeply appreciate Larry’s leadership and extraordinary contributions to the company and sincerely thank him for his 10 years of service and commitment to our mission.”
Cardiovascular Systems Inc., based in St. Paul, Minn., develops and commercializes solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. Food and Drug Administration (FDA) granted the first 510(k) clearance for the use of the Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the Coronary Orbital Atherectomy System. To date, over 356,000 of CSI’s devices have been sold to U.S. institutions.
